PTO/SB/17 (12-04y2/5)
Approved for use through 07/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
o a collection of information unless it displays a valid OMB control ork Reduction Act of 1995 no persons are required to res

Effective on 12/08/2004.

Fees: pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818).

# **FEE TRANSMIT** For FY 2005

<b>Applicant</b>	claims	small	entity sta	atus.	See	37	CFR	1.27

TOTAL AMOUNT OF PAYMENT (\$) 250.00

COUNTRY OF THE PROPERTY OF THE				
Complete if Known				
Application Number	10/714,333			
Filing Date	November 14, 2003			
First Named Inventor	KHVOROVA, Anastasia			
Examiner Name	EPPS-FORD, Dr. Janet L.			
Art Unit	1633			
Attorney Docket No.	DHARMA 0100-US2			

METHOD OF PAYME	NT (check al	I that apply)					
Check Credit Card Money Order None Other (please identify):    X   Deposit Account   Deposit Account Number: 11-0171   Deposit Account Name: Kalow & Springut LLP							
For the above-ider			tor is hereb	•	_	at apply)	
	s) indicated b			Г			cept for the filing fee
			nte of fools				cept for the ming fee
under 37 Cl WARNING: Information on the	Charge any additional fee(s) or underpayments of fee(s)  Credit any overpayments  under 37 CFR 1.16 and 1.17  WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.						
FEE CALCULATION							
1. BASIC FILING, SEA	RCH, AND	EXAMINATION	FEES		All .	THE PARTY OF THE P	
	FILING	FEES Small Entity	SEARC	H FEES Small Entity		TION FEES	
Application Type	Fee (\$)	Fee (\$)	Fee (\$)	Fee (\$)	Fee (\$)	Fee (\$)	Fees Paid (\$)
Utility	300	150	500	· 250	200	100	
· Design	200	100	100	50	130	65	
Plant	200	100	300	150	160	80	
Reissue	300	150	500	250	600	300	
. Provisional	200	100	0	0	0	0	
2. EXCESS CLAIM FEES Small Entity Fee Description Fee (\$) Fee (\$)							
Each claim over 20 (including Reissues) 50 25							
Each independent claim over 3 (including Reissues) 200 100							
Multiple dependent claims 360 180							
Total Claims         Extra Claims         Fee (\$)         Fee Paid (\$)         Multiple Dependent           20 or HP =         x =         Fee (\$)         Fee (\$)					Fee Pald (\$)		
HP = highest number of to	tal claims paid f	or, if greater than 20.		······································		100107	ree raid (4)
Indep. Claims - 3 or HP =	Extra Clair	ms Fee (\$)	Fee Pa	ald (\$)		<del></del>	
HP = highest number of ind	ependent claim	s paid for, if greater t	han 3.				<b>b</b> )
3. APPLICATION SIZE FEE If the specification and drawings exceed 100 sheets of paper (excluding electronically filed sequence or computer							
listings under 37 CFR 1.52(e)), the application size fee due is \$250 (\$125 for small entity) for each additional-50							
sheets or fraction Total Sheets - 100 =	Extra She	2 35 U.S.C. 41(a) ets Number /50 =	<u>er óf eách a</u>	d 37 CFR 1 additional 50 or round up to a	<u>or fráction th</u>	ereof Fee	(\$) Fee Paid (\$)
4. OTHER FEE(S) Non-English Specification, \$130 fee (no small entity discount)  Fees Paid (\$)							
Other (e.g., late filing surcharge): New claims fees for 5 new claims @ \$50/claim 250.00							

SUBMITTED BY Ja Sumbre Registration No. Signature (212) 813-1600 43,131 (Attorney/Agent) Date 21 October 2005 Name (Print/Type) **Tor SMELAND** 

This collection of information is required by 37 CFR 1.136. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 30 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**PATENT** 

#### **DOCKET DHARMA 0100-US2**

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

pplicants:

KHVOROVA et al.

Examiner:

EPPS-FORD, Dr. Janet L.

Serial No.:

10/714,333

Group Art Unit: 1633

Filed:

November 14, 2003

For:

Functional and Hyperfunctional siRNA

Customer No.:

23719

Kalow & Springut LLP

488 Madison Avenue, 19th Floor New York, New York 10022

October 21, 2005

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

#### **REPLY TO NOTICE TO COMPLY**

Dear Sir:

This Reply is in response to the Notice to Comply issued in the Non-final Office Action in this case on August 18, 2005. A response to the Office Action is due November 18, 2005. Thus, this Reply is timely filed.

10/26/2005 MBLANCO 00000009 110171 10714333

01 FC:1202

250.00 DA

#### Certificate of Mailing Under 37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited on the date shown below with the United States Postal Service as first class mail with sufficient postage in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



EVAN MCHALE

OCT 21, 2005

Applicants: KHVOROVA et al.

Serial No.: 10/714,333

Filing Date: November 14, 2003

Reply to Notice to Comply

October 21, 2005 Page 2 of 2

The following items are enclosed:

1. A copy of the Notice to Comply, issued in the Non-final Office Action in

this case mailed August 18, 2005;

2. Sequence listing in computer readable format (CRF) on CD-ROM (Copy 1

and Copy 2);

Paper copy of sequence listing submitted on CD-ROM in lieu of paper 3.

(Copy 1 and Copy 2);

4. A Sequence Listing Transmittal in Reply to Notice to Comply stating that

the content of the paper and computer readable copies are the same, and that no

new matter has been added;

5. An amendment requesting entry of the sequence listing into the

specification.

No fee is believed to be due in connection with this Reply. If any fee is deemed

necessary, or overpayment has been made, please charge, or credit, Deposit Account No.

11-0171.

If the Examiner has any questions regarding the present application, the Examiner

is cordially invited to contact Applicants' attorney at the telephone number provided

below.

Respectfully submitted,

Registration No.: 43,131

Attorney for Applicants

Kalow & Springut LLP

Telephone No.: (212) 813-1600



## **Notice to Comply**

Application No. 10/714,333	Applicant(s) KHVOROVA ET AL			
Examiner Janet L. Epps-Ford	Art Unit 1633			

### NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE **DISCLOSURES**

Applicant must file the items indicated below within the time period set in the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with

uic	requirements for such a disclosure as set lottle in 57 C.F.R. 1.021 - 1.025 for the following reason(s):
$\boxtimes$	1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
	2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
	6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
	7. Other: Figure 13 recites multiple sequences of 10 nucleotides or greater, they are not assigned a SEQ ID NO.
	plicant Must Provide:
$\boxtimes$	An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
	An initial or substitute paper copy of the "Sequence Listing", as well as an amendment ecifically directing its entry into the specification.
$\boxtimes$	A statement that the content of the paper and computer readable copies are the same and, where

1.825(d).

applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (571) 272-2510

For CRF Submission Help, call (571) 272-2501/2583.

Patentin Software Program Support

Technical Assistance......703-287-0200

To Purchase Patentin Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY